| answer text |
<p>The Department regularly discusses a range of issues with colleagues in NHS England
related to patient access to new medicines. The National Institute for Health and
Care Excellence (NICE) makes recommendations for the National Health Service on whether
all new medicines should be routinely funded by the NHS, based on an assessment of
their costs and benefits. The NICE’s appraisal of the gene therapy, exagamglogene
autotemcel, for treating transfusion-dependent beta-thalassaemia is currently paused,
to allow the company and NHS England to enter into commercial and managed access discussions.</p><p>In
November 2023, NHS England published a clinical commissioning policy that recommends
that allogeneic haematopoietic stem cell transplantation for adult transfusion dependent
thalassaemia should be routinely commissioned.</p>
|
 |
